IL1A and rheumatoid arthritis: IL-1RA competes with IL-1α or IL-1β for binding to IL-1 receptor (IL-1R1) resulting in suppression of IL-1 activity and has been already approved for use in humans for the treatment of rheumatoid arthritis.